Legend Biotech (LEGN) Gross Margin (2019 - 2025)
Legend Biotech (LEGN) reported Gross Margin of 79.04% for Q4 2025, up 526.0% on a YoY basis from 12.63% in Q4 2024, and down 2.04% quarter-over-quarter from 80.68% in Q3 2025.
Legend Biotech (LEGN) Gross Margin (2019 - 2025) Analysis & Trends
Legend Biotech has reported Gross Margin for 7 years, with the latest figure at 79.04% in Q4 2025.
- For the quarter ending Q4 2025, Gross Margin rose 526.0% year-over-year to 79.04%; the trailing twelve-month figure through Dec 2025 stood at 79.99% (up 350.0% YoY), and the FY2025 full-year result was 80.0%, up 351.0% from the prior year.
- Gross Margin for Q4 2025 stood at 79.04%, down from 80.68% in the prior quarter.
- The five-year high for Gross Margin was 100.0% in Q4 2023, with the low at 97963.15% in Q1 2021.
- Historically, Gross Margin has averaged 4855.39% across 5 years, with a median of 71.57% in 2023.
- Annual changes were most pronounced in 2021 — Gross Margin sank 9800646 bps — and 2022, when it surged 9802058 bps.
- Legend Biotech's Gross Margin stood at 35.43% in 2021, then soared by 118 bps to 6.55% in 2022, then jumped by 1427 bps to 100.0% in 2023, then retreated by 26 bps to 73.78% in 2024, then increased by 7 bps to 79.04% in 2025.
- The last three Gross Margin figures came in at 79.04% (Q4 2025), 80.68% (Q3 2025), and 81.16% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 91.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 79.04% |
| Sep 30, 2025 | 80.68% |
| Jun 30, 2025 | 81.16% |
| Mar 31, 2025 | 79.00% |
| Dec 31, 2024 | 73.78% |
| Sep 30, 2024 | 72.37% |
| Jun 30, 2024 | 83.88% |
| Mar 31, 2024 | 74.23% |
| Dec 31, 2023 | 100.00% |
| Sep 30, 2023 | 78.03% |
| Jun 30, 2023 | 70.78% |
| Mar 31, 2023 | 50.59% |
| Dec 31, 2022 | 6.55% |
| Sep 30, 2022 | 31.10% |
| Jun 30, 2022 | -129.22% |
| Mar 31, 2022 | 57.43% |
| Dec 31, 2021 | -35.43% |
| Sep 30, 2021 | -15.70% |
| Jun 30, 2021 | 17.06% |
| Mar 31, 2021 | -97,963.15% |